The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years

被引：429

作者：

Brown, Darron R. ^{[1
]}

Kjaer, Susanne K. ^{[2
]}

Sigurdsson, Kristjan ^{[3
]}

Iversen, Ole-Erik ^{[4
,5
]}

Hernandez-Avila, Mauricio ^{[6
]}

Wheeler, Cosette M. ^{[7
,8
]}

Perez, Gonzalo ^{[9
]}

Koutsky, Laura A. ^{[10
]}

Tay, Eng Hseon ^{[11
]}

Garcia, Patricia ^{[12
]}

Ault, Kevin A. ^{[13
]}

Garland, Suzanne M. ^{[14
,15
]}

Leodolter, Sepp ^{[16
]}

Olsson, Sven-Eric ^{[17
]}

Tang, Grace W. K. ^{[18
]}

Ferris, Daron G. ^{[19
]}

Paavonen, Jorma ^{[20
]}

Steben, Marc ^{[21
]}

Bosch, F. Xavier ^{[22
]}

Dillner, Joakim ^{[23
]}

Joura, Elmar A. ^{[16
]}

Kurman, Robert J. ^{[24
,25
]}

Majewski, Slawomir ^{[26
]}

Munoz, Nubia ^{[27
]}

Myers, Evan R. ^{[28
]}

Villa, Luisa L. ^{[29
]}

Taddeo, Frank J. ^{[30
]}

Roberts, Christine ^{[30
]}

Tadesse, Amha ^{[30
]}

Bryan, Janine ^{[30
]}

Lupinacci, Lisa C. ^{[30
]}

Giacoletti, Katherine E. D. ^{[30
]}

Sings, Heather L. ^{[30
]}

James, Margaret ^{[30
]}

Hesley, Teresa M. ^{[30
]}

Barra, Eliav ^{[30
]}

机构：

[1] Indiana Univ, Sch Med, Indianapolis, IN 46202 USA

[2] Rigshosp, Danish Canc Soc, Dept Virus Hormones & Canc, Inst Canc Epidemiol, DK-2100 Copenhagen, Denmark

[3] Natl Canc Detect Clin, Reykjavik, Iceland

[4] Univ Bergen, Dept Clin Med, Bergen, Norway

[5] Haukeland Hosp, Dept Obstet & Gynecol, N-5021 Bergen, Norway

[6] Inst Publ Hlth, Cuernavaca, Morelos, Mexico

[7] Univ New Mexico, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA

[8] Univ New Mexico, Dept Obstet & Gynecol, Albuquerque, NM 87131 USA

[9] Univ Rosario, Bogota, Colombia

[10] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA

[11] KK Womens & Childrens Hosp, Singapore, Singapore

[12] Univ Peruana Cayetano Heredia, Epidemiol HIV & STD Unit, Lima, Peru

[13] Emory Univ, Sch Med, Dept Gynecol & Obstet, Atlanta, GA 30322 USA

[14] Univ Melbourne, Microbiol & Infect Dis Dept, Royal Womens Hosp, Melbourne, Vic, Australia

[15] Univ Melbourne, Dept Obstet & Gynecol, Melbourne, Vic, Australia

[16] Med Univ Vienna, Dept Gynecol & Obstet, Vienna, Austria

[17] Karolinska Inst, Danderyd Hosp, Stockholm, Sweden

[18] Univ Hong Kong, Dept Obstet & Gynecol, Hong Kong, Hong Kong, Peoples R China

[19] Med Coll Georgia, Dept Family Med & Obstet & Gynecol, Augusta, GA 30912 USA

[20] Univ Cent Hosp, Dept Obstet & Gynecol, Helsinki, Finland

[21] Inst Natl Sante Publ Quebec, Direct Risques Biol Environm & Occupat, Montreal, PQ, Canada

[22] IDIBELL, Inst Catala Oncol, Barcelona, Spain

[23] Lund Univ, Dept Med Microbiol, Lund, Sweden

[24] Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, Baltimore, MD USA

[25] Johns Hopkins Univ, Sch Med, Dept Pathol & Oncol, Baltimore, MD USA

[26] Warsaw Med Univ, Dept Dermatol & Venereol, Ctr Diagnost & Treatment Sexually Transmitted Dis, Warsaw, Poland

[27] Natl Canc Inst, Bogota, Colombia

[28] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC USA

[29] Ludwig Inst Canc Res, Dept Virol, Sao Paulo, Brazil

[30] Merck Res Labs, West Point, PA USA

来源：

JOURNAL OF INFECTIOUS DISEASES | 2009年 / 199卷 / 07期

关键词：

GRADE CERVICAL LESIONS; DOUBLE-BLIND; YOUNG-WOMEN; EFFICACY; CANCER; CLASSIFICATION;

D O I：

10.1086/597307

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background. Human papillomavirus (HPV)-6/11/16/18 vaccine reduces the risk of HPV-6/11/16/18-related cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS). Here, its impact on CIN1-3/AIS associated with nonvaccine oncogenic HPV types was evaluated. Methods. We enrolled 17,622 women aged 16-26 years. All underwent cervicovaginal sampling and Pap testing at regular intervals for up to 4 years. HPV genotying was performed for biopsy samples, and histological diagnoses were determined by a pathology panel. Analyses were conducted among subjects who were negative for 14 HPV types on day 1. Prespecified analyses included infection of >= 6 months' duration and CIN1-3/AIS due to the 2 and 5 most common HPV types in cervical cancer after HPV types 16 and 18, as well as all tested nonvaccine types. Results. Vaccination reduced the incidence of HPV-31/45 infection by 40.3% (95% confidence interval [CI], 13.9% to 59.0%) and of CIN1-3/AIS by 43.6% (95% CI, 12.9% to 64.1%), respectively. The reduction in HPV-31/33/45/52/58 infection and CIN1-3/AIS was 25.0% (95% CI, 5.0% to 40.9%) and 29.2% (95% CI, 8.3% to 45.5%), respectively. Efficacy for CIN2-3/AIS associated with the 10 nonvaccine HPV types was 32.5% (95% CI, 6.0% to 51.9%). Reductions were most notable for HPV-31. Conclusions. HPV-6/11/16/18 vaccine reduced the risk of CIN2-3/AIS associated with nonvaccine types responsible for similar to 20% of cervical cancers. The clinical benefit of cross-protection is not expected to be fully additive to the efficacy already observed against HPV-6/11/16/18-related disease, because women may have >1 CIN lesion, each associated with a different HPV type.

引用

页码：926 / 935

页数：10

共 27 条

[11] Epidemiologic classification of human papillomavirus types associated with cervical cancer
Muñoz, N
Bosch, FX
de Sanjosé, S
Herrero, R
Castellsagué, X
Shah, KV
Snijders, PJF
Meijer, CJLM
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) : 518 - 527
[12] National Cancer Institute, CANC ADV FOC CERV CA
[13] Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine
Olsson, Sven-Eric
Villa, Luisa L.
Costa, Ronaldo L. R.
Petta, Carlos A.
Andrade, Rosires P.
Malm, Christian
Iversen, Ole-Erik
Hoye, John
Steinwall, Margareta
Riis-Johannessen, Grete
Andersson-Ellstrom, Agneta
Elfgren, Kristina
von Krogh, Geo
Lehtinen, Matti
Paavonen, Jorma
Tamms, Gretchen M.
Giacoletti, Katherine
Lupinacci, Lisa
Esser, Mark T.
Vuocolo, Scott C.
Saah, Alfred J.
Barr, Eliav
[J]. VACCINE, 2007, 25 (26) : 4931 - 4939
[14] Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women:: an interim analysis of a phase III double-blind, randomised controlled trial
Paavonen, Jorma
Jenkins, David
Bosch, F. Xavier
Naud, Paulo
Salmeron, Jorge
Wheeler, Cosette M.
Chow, Song-Nan
Apter, Dan L.
Kitchener, Henry C.
Castellsague, Xavier
de Carvalho, Newton S.
Skinner, S. Rachel
Harper, Diane M.
Hedrick, James A.
Jaisamrarn, Unnop
Limson, Genara A. M.
Dionne, Marc
Quint, Wim
Spiessens, Bart
Peeters, Pascal
Struyf, Frank
Wieting, Susan L.
Lehtinen, Matti O.
Dubin, Gary
[J]. LANCET, 2007, 369 (9580) : 2161 - 2170
[15] American Cancer Society guideline for human papillornavirus (HPV) vaccine use to prevent cervical cancer and its precursors
Saslow, Debbie
Castle, Philip E.
Cox, J. Thomas
Davey, Diane D.
Einstein, Mark H.
Ferris, Daron G.
Goldie, Sue J.
Harper, Diane M.
Kinney, Walter
Moscicki, Anna-Barbara
Noller, Kenneth L.
Wheeler, Cosette M.
Ades, Terri
Andrews, Kimberly S.
Doroshenk, Mary K.
Green Kahn, Kelly
Schmidt, Christy
Shafey, Omar
Smith, Robert A.
Partridge, Edward E.
[J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2007, 57 (01) : 7 - 28
[16] Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update
Smith, Jennifer S.
Lindsay, Lisa
Hoots, Brooke
Keys, Jessica
Franceschi, Silvia
Winer, Rachel
Clifford, Gary M.
[J]. INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (03) : 621 - 632
[17] Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ:: a combined analysis of four randomised clinical trials
Villa, L.
Perez, G.
Kjaer, S.
Lehtinen, M.
Paavonen, J.
Munoz, N.
Sigurdsson, K.
Hernandez-Avila, M.
Iversen, O. E.
Thoresen, S.
Garcia, P.
Majewski, S.
Tay, E. H.
Bosch, F. X.
Dillner, J.
Olsson, S. E.
Ault, K.
Brown, D.
Ferris, D.
Giuliano, A.
Koutsky, L.
Kurman, R.
Myers, E.
Barr, E.
Boslego, J.
Bryan, J.
Esser, M.
Hesley, T.
Lupinacci, L.
Railkar, R.
Sings, H.
Taddeo, F.
Thornton, A.
[J]. LANCET, 2007, 369 (9576) : 1861 - 1868
[18] Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
Villa, LL
Costa, RLR
Petta, CA
Andrade, RP
Ault, KA
Giuliano, AR
Wheeler, CM
Koutsky, LA
Malm, C
Lehtinen, M
Skjeldestad, FE
Olsson, SE
Steinwall, M
Brown, DR
Kurman, R
Ronnett, BM
Stoler, MH
Ferenczy, A
Harper, DM
Tamms, GM
Yu, J
Lupinacci, L
Railkar, R
Taddeo, FJ
Jansen, KU
Esser, MT
Sings, HL
Saah, AJ
Lupinacci, L
[J]. LANCET ONCOLOGY, 2005, 6 (05) : 271 - 278
[19] Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection
Villa, Luisa L.
Perez, Gonzalo
Kjaer, Susanne Krueger
Paavonen, Jorma
Lehtinen, Matti
Munoz, Nubia
Sigurdsson, Kristjan
Hernandez-Avila, Mauricio
Iversen, Ole Eric
Thoresen, Steinar
Garcia, Patricia J.
Majewski, Slawomir
Tay, Eng Hseon
Bosch, F. Xavier
Dillner, Joakim
Olsson, Sven-Eric
Ault, Kevin A.
Brown, Darron R.
Ferris, Daron G.
Koutsky, Laura A.
Kurman, Robert J.
Myers, Evan R.
Barr, Eliav
Boslego, John
Bryan, Janine
Esser, Mark T.
Hesley, Teresa M.
Nelson, Micki
Railkar, Radha
James, Margaret
Sattler, Carlos
Taddeo, Frank J.
Thornton, Annemarie R.
Vuocolo, Scott C.
[J]. JOURNAL OF INFECTIOUS DISEASES, 2007, 196 (10) : 1438 - 1446
[20] Villa LL, 2007, NEW ENGL J MED, V356, P1915, DOI 10.1056/NEJMoa061741

← 1 2 3 →